Abstract
Background: Until now, multiple reviews on the pharmacological treatment of dementia have been published. Methods: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia. Conclusions: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade. (C) 2013 S. Karger AG, Basel
| Original language | English |
|---|---|
| Pages (from-to) | 211-228 |
| Number of pages | 18 |
| Journal | Dementia and Geriatric Cognitive Disorders |
| Volume | 36 |
| Issue number | 3-4 |
| DOIs | |
| Publication status | Published - 2013 |
| Externally published | Yes |
Keywords
- Systematic reviews
- Evidence-based medicine
- Dementia
- Scoping review
- Pharmacological treatment
- Alzheimer's disease
- Vascular dementia
- Lewy body disease
- Parkinson dementia
- Frontotemporal dementia
- SEVERE ALZHEIMERS-DISEASE
- PSYCHOLOGICAL SYMPTOMS
- MEMANTINE
- EFFICACY
- MODERATE
- DONEPEZIL
- RIVASTIGMINE
- TOLERABILITY
- METAANALYSIS
- GALANTAMINE
Fingerprint
Dive into the research topics of 'Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver